Pulmatrix Licenses Novel Drug Candidates from RespiVert Ltd., a wholly owned subsidiary of Janssen Biotech, Inc.

Stock Information for Pulmatrix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Pulmatrix Inc.

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.